• In early May 2026, Novavax reported first-quarter revenue of US$139.51 million versus US$666.66 million a year earlier, swinging from net income of US$518.65 million to a net loss of US$9.49 million and posting basic and diluted loss per share of US$0.06 from continuing operations.

  • Despite the year-on-year drop in sales and profitability, Novavax’s quarterly results exceeded market expectations and were underpinned by new Matrix-M licensing activity, including an upfront US$30 million payment from a Pfizer agreement that underscores the growing commercial interest in its adjuvant platform.

  • We’ll now examine how the Pfizer Matrix-M licensing deal and stronger-than-expected first-quarter results influence Novavax’s partnership-led investment narrative.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

Novavax Investment Narrative Recap

To own Novavax today, you need to believe its partner-first model can offset lumpier COVID-19 vaccine revenue and support a path back to sustainable profitability. The Pfizer Matrix-M licensing deal and stronger than expected first quarter numbers support that partnership narrative in the near term, but they do not remove the key risk that milestone and royalty income from a small set of partners may remain volatile and heavily timing dependent.

The Pfizer Matrix-M agreement, which delivered an upfront US$30 million in the first quarter, looks most relevant here. It not only helped Novavax beat expectations on revenue and narrow its loss, it also reinforces the idea that third parties see value in Matrix-M across multiple vaccine fields, which could become an important offset if COVID-19 demand proves weaker or more unpredictable than hoped.

Yet, against this progress, investors should also be aware that reliance on a few large partners could quickly become a problem if…

Read the full narrative on Novavax (it’s free!)

Novavax’s narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax’s forecasts yield a $13.78 fair value, a 36% upside to its current price.

Exploring Other Perspectives NVAX 1-Year Stock Price Chart NVAX 1-Year Stock Price Chart

Before this news, the most optimistic analysts were still modeling falling annual revenue to about US$306.6 million and earnings of roughly US$38.4 million, so compared with the baseline concerns about partner concentration, their view leans far more upbeat about Matrix-M licensing potential, highlighting how your own stance on these assumptions may shift as new deals and quarterly results come through.

Explore 4 other fair value estimates on Novavax – why the stock might be worth just $13.78!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

No Opportunity In Novavax?

Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NVAX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com